Private health insurers have yet to publish coverage criteria for new postpartum depression drug zuranolone, despite it hitting the market in December.
New postpartum depression drug zuranolone, which hit the market in December, is yet to have coverage criteria published by most private health insurers, according to a new analysis of insurance policies. The drug, which targets hormone function to relieve symptoms and costs $15,900 for a 14-day pill regimen, is<|im_start|> being closely watched by lawyers, advocates, and regulators due to concerns about how insurers handled zuranolone's predecessor, brexanolone, which came on the market in 2019.
March 12, 2024
27 Articles